Brain & NeurologyLLLT demonstrated an early between-group advantage over MT at 4 weeks in pain reduction and sensorimotor recovery in post-stroke CRPS-I. However, in the long run, no overall between-group superiority was noted, as both groups achieved comparable outcomes.
Trial · October 1, 2026 · De SK et al.
Brain & NeurologyMonotherapies provided moderate yet meaningful protection.
Study · September 7, 2026 · Kayani H et al.
Brain & NeurologyPharmacological p53 inhibition with PFT-α or UFL1 knockdown in donor EVs substantially diminished these therapeutic effects in vivo, confirming the central role of the UFL1/p53 axis.
Study · August 18, 2026 · Fang Y et al.